- Home
- LVTX vs FGEN Comparison
LVTX vs FGEN Comparison
Compare LVTX & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LVTX
- FGEN
- Stock Information
- Founded
- LVTX 2016
- FGEN 1993
- Country
- LVTX Netherlands
- FGEN United States
- Employees
- LVTX N/A
- FGEN N/A
- Industry
- LVTX Biotechnology: Pharmaceutical Preparations
- FGEN Biotechnology: Pharmaceutical Preparations
- Sector
- LVTX Health Care
- FGEN Health Care
- Exchange
- LVTX Nasdaq
- FGEN Nasdaq
- Market Cap
- LVTX 33.9M
- FGEN 33.5M
- IPO Year
- LVTX 2021
- FGEN 2014
- Fundamental
- Price
- LVTX $1.43
- FGEN $7.45
- Analyst Decision
- LVTX Hold
- FGEN Strong Buy
- Analyst Count
- LVTX 3
- FGEN 1
- Target Price
- LVTX $1.75
- FGEN $250.00
- AVG Volume (30 Days)
- LVTX 30.6K
- FGEN 48.5K
- Earning Date
- LVTX 08-19-2025
- FGEN 08-05-2025
- Dividend Yield
- LVTX N/A
- FGEN N/A
- EPS Growth
- LVTX N/A
- FGEN N/A
- EPS
- LVTX N/A
- FGEN N/A
- Revenue
- LVTX $4,990,000.00
- FGEN $6,996,000.00
- Revenue This Year
- LVTX N/A
- FGEN N/A
- Revenue Next Year
- LVTX N/A
- FGEN N/A
- P/E Ratio
- LVTX N/A
- FGEN N/A
- Revenue Growth
- LVTX N/A
- FGEN N/A
- 52 Week Low
- LVTX $0.85
- FGEN $4.50
- 52 Week High
- LVTX $2.21
- FGEN $33.49
- Technical
- Relative Strength Index (RSI)
- LVTX 58.31
- FGEN 55.79
- Support Level
- LVTX $1.40
- FGEN $7.31
- Resistance Level
- LVTX $1.67
- FGEN $7.82
- Average True Range (ATR)
- LVTX 0.10
- FGEN 0.59
- MACD
- LVTX 0.00
- FGEN 0.10
- Stochastic Oscillator
- LVTX 33.33
- FGEN 69.35
About LVTX LAVA Therapeutics N.V.
LAVA Therapeutics NV isa clinical stage immuno-oncology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer. Company's pipeline include's products such as LAVA-1266, LAVA-1427, LAVA-1433, LAVA-1207, PF08046052, JNJ89853413.
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.